Merck Cuts Pharma Revenue Guidance By $1.7bn Due To Pandemic
Executive Summary
Overall, the pharma lowered its 2020 revenue guidance by $2.5bn at the midpoint, but also says it will save about $400m on SG&A expenses. Pandemic impacts expected mainly in Q2, normal resumption in Q4.
You may also be interested in...
Merck & Co's Gerberding Adds Dose Of Reality To COVID-19 Debate
The US giant's chief patient officer and former head of the CDC, is proud of the "incredible collaboration" going on across the biopharmaceutical industry to tackle coronavirus but says "we have to be honest that we really don't understand this disease."
Amgen Optimistic About 2020 Despite COVID-19 Impacts
Relatively upbeat during the company’s Q1 call based on Amgen’s product mix, executives expect the biggest coronavirus-related sales impacts in Q2 with stabilization and growth in the second half.
China The Light In The Tunnel? Merck Thinks So
As the first major country apparently emerging from the coronavirus outbreak, China offers a ray of hope for healthcare companies struggling with a large drop in prescriptions and vaccine use as the outbreak continues to wreak havoc in the US, Europe, Japan and emerging markets.